Iambic Therapeutics utilizes a physics-based AI-driven drug discovery platform to explore chemical space and identify novel mechanisms of action for drug candidates. The platform accelerates the development of first-in-class therapeutics by optimizing target product profiles and delivering high-quality leads at a pace significantly faster than traditional methods.
Funding
$209.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
EVMCFounders
Product
Problem
Traditional drug discovery methods are slow and inefficient, often failing to identify novel mechanisms of action or optimize drug candidates effectively. Exploring the vast chemical space for potential therapeutics is challenging, leading to delays in developing first-in-class treatments.
Solution
Iambic Therapeutics utilizes a physics-based, AI-driven drug discovery platform to accelerate the identification and development of optimized medicines. The platform employs high-throughput experimentation, converting new molecular designs into biological insights to optimize target product profiles. By deeply exploring chemical space, the platform reveals novel mechanisms of action and delivers high-quality leads at a pace significantly faster than traditional methods. This approach unlocks the potential of known targets and transforms seemingly undruggable targets into opportunities for breakthrough treatments.
Target Audience
The primary audience includes pharmaceutical companies and research institutions focused on developing novel therapeutics, particularly in oncology.
Features
- Physics-based AI algorithms for accurate and data-efficient drug discovery
- High-throughput experimental platform for rapid iteration from molecular design to biological data
- Parallel optimization of multiple target product profiles to address disease biology
- Identification of novel mechanisms of action through deep exploration of chemical space
- Pipeline of differentiated clinical candidates delivered faster than industry standards
- Focus on unlocking untapped potential of known targets and addressing undruggable targets
- Programs targeting cryptic pockets, allostery, and protein-protein interactions across multiple therapeutic areas